Splenic Marginal Zone Lymphoma clinical trials
5 active trials name this condition. Describe your situation to see which ones you may be eligible for.
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- Study of SGR-1505 in Mature B-Cell Neoplasms
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Splenic Marginal Zone Lymphoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.